Filter
34
Text search:
Covishield
Featured
Recommendations
9
Language
Document type
Guidelines
17
Fact sheets
10
Manuals
4
Studies & Reports
1
Situation Updates
1
Resource Platforms
1
Countries / Regions
Argentina
7
India
3
Brazil
3
South Sudan
1
Syria
1
Ukraine
1
Ecuador
1
East and Southern Africa
1
West and Central Africa
1
Latin America and the Carribbean
1
Authors & Publishers
Publication Years
Category
Countries
18
Clinical Guidelines
1
Toolboxes
COVID-19
32
Conflict
2
Refugee
1
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato
...
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc
...
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir
...
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto
...
Considerations for implementing and adjusting public health and social measures in the context of COVID-19
recommended
interim guidance, 14 June 2021
This document is intended for national authorities and decision makers in countries that have introduced large scale public health and social measures. It offers guidance for adjusting public health and social measures, while managing the risk of a resurgence of cases
...
orientations provisoires, 14 juin 2021
Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19
recommended
orientaciones provisionales, 14 de junio de 2021
Considerations on the implementation and adjustment of
public health and social measures in the context of
COVID-19
Interim guidance 14 June 2021
7 April 2021
Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.
Available in Englisch, French and Russian
This situation update is on the Novel Coronavirus (COVID-19) reported cases and deaths, Globally, Regionally, for Barbados and the Eastern Caribbean Countries, French Territories, and the United Kingdom Overseas Territories.
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel
